AWINSA
LIFE SCIENCES
Attitude to WIN with Sapience

SGLT2 inhibitors: beyond efficacy to safety considerations



Background

The management of type 2 diabetes mellitus (T2DM) has witnessed a paradigm shift over the last decade. With the rise in global prevalence of T2DM and its associated complications, the need for effective, long-term management strategies has been paramount. While traditional therapies focus primarily on insulin secretion and sensitivity, newer classes of drugs have targeted different aspects of the complex pathophysiology of diabetes.

SGLT2 inhibitors are one such class. Introduced in the 2010s, they represent a novel approach, targeting renal glucose reabsorption. By inhibiting the SGLT2 protein in the kidneys, these drugs prevent reabsorption of glucose from the renal tubules, leading to glucose excretion in urine. This unique mechanism not only aids in glucose control but also provides benefits like weight reduction and blood pressure management due to its osmotic diuretic effect.

Given their potential benefits, SGLT2 inhibitors quickly garnered attention in the medical community. However, with more extensive use and post-marketing surveillance, various safety concerns have come to the forefront.

Introduction

SGLT2 inhibitors have emerged as promising agents in the management of T2DM. While demonstrating benefits in glycemic control, weight management, and cardiovascular outcomes, they also come with potential adverse effects. This article aims to provide a comprehensive overview of the safety concerns associated with these agents.

A New Dawn: The Mechanism of SGLT2 Inhibitors:

SGLT2 inhibitors, or Sodium-Glucose Co-transporter 2 inhibitors, offer a distinct mode of action. Unlike other antidiabetic drugs, they work by inhibiting glucose reabsorption in the kidneys. The result? An increased glucose excretion via urine, leading to improved glycemic control. This renal-centric approach also paves the way for secondary benefits like osmotic diuresis and blood pressure reduction.

The Bright Side: Clinical Benefits of SGLT2 Inhibitors

1. **Cardiovascular Outcomes:**

Studies have indicated that SGLT2 inhibitors reduce the risk of major cardiovascular events, especially in those with a history of heart disease.

2. **Nephroprotection:**

These agents have shown a potential to slow the progression of kidney disease in diabetic patients, making them a favorable choice for those with concurrent renal impairments.

3. Weight Reduction:

Due to increased glucose excretion, patients often experience modest weight loss, an added advantage in the management of T2DM.

4. Blood Pressure Regulation:

Their osmotic diuretic effect aids in mild blood pressure reduction, beneficial for hypertensive diabetics.



The Other Edge: Potential Hazards of SGLT2 Inhibitors

1. Genital and Urinary Tract Infections:

One of the most frequently reported side effects of SGLT2 inhibitors is the increased risk of genital and urinary tract infections. These infections are primarily fungal, often candidal in nature, and are especially prevalent among women. The increased glucose concentration in urine due to the drug's mechanism provides a favorable environment for yeast overgrowth.

2. Diabetic Ketoacidosis (DKA):

An alarming adverse effect is the risk of DKA, a life-threatening condition. What's intriguing is the atypical presentation of DKA in patients using SGLT2 inhibitors—euglycemic DKA. Patients might not exhibit significantly elevated blood sugars, which can delay diagnosis and intervention.

3. **Bone Health and Fracture:**

Canagliflozin, in particular, has been associated with decreased bone mineral density and an increased risk of bone fractures. The exact mechanism remains unclear, but it's speculated that the drug's impact on renal phosphate handling might be a contributing factor.

4. **Lower Limb Amputations:**

The CANVAS trial spotlighted a potential association between canagliflozin and an increased risk of lower limb amputations. While subsequent studies haven't consistently echoed this concern for all SGLT2 inhibitors, it's a consideration for clinicians when prescribing, especially in patients with pre-existing peripheral vascular disease.

5. **Kidney Considerations:**

Although there are instances of acute kidney injuries with SGLT2 inhibitors, these agents have also been shown to offer nephroprotective effects, especially in diabetic patients with renal impairment. The renal benefits seem to outweigh the risks, but monitoring is crucial.

6. **Fournier's Gangrene:**

A rare but life-threatening bacterial infection, Fournier's Gangrene has been reported in patients using SGLT2 inhibitors. It's a necrotizing fasciitis that affects the genital or perineal region and requires prompt diagnosis and treatment.

7. **Volume Depletion and Hypotension:**

Given the diuretic action of SGLT2 inhibitors, they can cause volume depletion. This is particularly relevant during initiation and can lead to dizziness, dehydration, or hypotension, especially in elderly patients or those on concomitant diuretics.

8. **Lipid Profile Alterations:**

A slight elevation in LDL cholesterol has been observed in some patients on SGLT2 inhibitors. The clinical significance of this increase, especially concerning cardiovascular outcomes, remains a subject of ongoing research.

9. **Rare but Noteworthy Effects:**

Lower Limb Ischemia: Emerging data suggests a potential increased risk, warranting more research.

Drug Interactions: Particularly with diuretics and drugs affecting kidney function, interactions can potentiate the risk of volume depletion or kidney injury.

Conclusion

The introduction of SGLT2 inhibitors has undeniably broadened the therapeutic arsenal for T2DM. Their benefits in cardiovascular outcomes and renal protection are remarkable. However, as clinicians, it's paramount to recognize and promptly address the potential adverse effects associated with them. Patient education, frequent monitoring, and individualized treatment approaches are the keystones for optimizing therapy with these agents.

References

1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. **The New England Journal of Medicine**. 2015;373(22):2117-2128.
2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. **The New England Journal of Medicine**. 2017;377(7):644-657.
3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. **The New England Journal of Medicine**. 2019;380(4):347-357.
4. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium-glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. **Diabetes, Obesity and Metabolism**. 2014;16(5):457-466.
5. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition. **Diabetes Care**. 2015;38(9):1687-1693.
6. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. U.S. **Food and Drug Administratio**n. 2015.
7. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. **The Journal of Clinical Endocrinology & Metabolism**. 2016;101(1):157-166.
8. FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). **U.S. Food and Drug Administration.** 2017. [Website Link].
9. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. **Annals of Internal Medicine**. 2019;170(11):764-769.

About AWINSA

Planning for a paradigm shift in the delivery of Pharmacovigilance services, AWINSA Life Sciences aims to provide end to end PV services including in its ambit both clinical trial and post marketing services. Manned by people with discernment and an eye for quality, we at AWINSA Life Sciences ensure astute analysis of safety reports so that clinical scenarios emerge in perspicuity. Intricate and deep-rooted knowledge of the subject and the international regulations will ensure that you are delivered services of the highest order within the stringent timelines.

Contact Us

INDIA: E13/9 First floor, Vasant Vihar, New Delhi 110057

NORTH AMERICA: 59 E, Shrewsbury Place Princeton, NJ 08540 United States

EU: Wilhelmina Druckerlaan 10, 6532 SR, Nijmegen, The Netherlands

LATIN AMERICA: Cerrada Ahuizotla 53, Col. Santiago Ahuizotla, Del. Azcapotzalco CP.02750 Ciudad de México, México

Business Enquiries: info@awinsals.com|www.awinsals.com

We welcome your comments and reserve the right to revise this publication and/or make improvements or changes this publication at any time.